Document:

Exhibit 10.6

 

THE SECURITIES REPRESENTED
HEREBY, INCLUDING THE SHARES ISSUABLE UPON EXERCISE
HEREOF, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES
LAWS AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND
SUCH LAWS WHICH, IN THE OPINION OF COUNSEL FOR THE ISSUER, IS AVAILABLE.

 

WARRANT
AGREEMENT

 

No.
2

 

HEALTHLYNKED
CORPORATION

 

This
Warrant Agreement (this “Agreement”) is dated as of July 11, 2016 (the “Issue Date”)
and entered into by and between HealthLynked Corporation, a corporation organized under the laws of State of Nevada and Delaney
Equity Group, LLC (together with its successors and assigns, the “Warrant Holder or DEG”).

 

WHEREAS,
the Company and the Warrant Holder entered into an Engagement Letter dated November 2, 2015 (the “Engagement Letter”),
and subsequent addendum dated December 6, 2016 pursuant to which, the Warrant Holder and Company agreed to compensate DEG 277,778
warrants of common stock of HealthLynked Corporation based upon 5% warrant coverage of net proceeds of $500,000 of debt or $25,000
at $0.09/warrant share; and

 

WHEREAS,
all of the terms and conditions of such Engagement Letter are incorporated herein by this reference, and all capitalized terms
not separately defined in this Warrant, shall have the same meanings as defined in the Engagement Letter and all subsequent addendums.

 

NOW,
THEREFORE, in consideration of the mutual covenants set forth in this Agreement and for other good and valuable consideration,
the parties agree as follows:

 

1. Grant
of Warrant. The Company hereby, upon the terms and subject to the conditions of this Agreement, issues to the Warrant
Holder a warrant (the “Warrant”) evidenced by this Agreement to purchase up to that number of Conversion Securities
as shall be equal to 277,778 warrants at an exercise price of $0.09 per share pursuant to the terms hereof, the “Exercise
Price”).

 

2. Term
and Termination of Warrant. The Warrant shall terminate on the fifth (5th) anniversary of the Issue Date (the “Expiration
Date”).

 

3. Exercise
of the Warrant.

 

(a) Exercise
and Payment. The purchase rights represented by the Warrant may be exercised by the Warrant Holder, in whole or in part at
any time following the Issue Date during the period prior to the Expiration Date, by the surrender of the Warrant (together with
a duly executed notice of exercise in the form attached hereto as Exhibit A (the “Exercise Notice”)
at the principal office of the Company, and by the payment to the Company, at the option of the Warrant Holder by wire transfer
of immediately available funds, of an amount equal to (A) the number of Warrant Shares being purchased upon exercise of the Warrant
multiplied by (B) the Exercise Price (the “Warrant Price”).

 

     

     

    

 

(b) Warrant
Shares. On or before the first (1st) Business Day (as hereafter defined) following the date on which the Company
has received an Exercise Notice, the Company shall transmit by facsimile an acknowledgment or confirmation of receipt of such
Exercise Notice to the Holder. On or before the third (3rd) Business Day following the date on which the Company has
received such Exercise Notice, so long as the Holder delivers the Aggregate Exercise Price on or prior to the second (2nd)
Business Day following the date on which the Company has received such Exercise Notice, the Company shall issue and deliver to
the Holder or, at the Holder’s instruction pursuant to the Exercise Notice, the Holder’s agent or designee, in each
case, sent by reputable overnight courier to the address as specified in the applicable Exercise Notice, a certificate, registered
in the Company’s shareholder register in the name of the Holder or its designee (as indicated in the applicable Exercise
Notice), representing the number of Warrant Shares to which the Holder is entitled pursuant to such exercise. The Company shall
be responsible for all fees and expenses related to the issuance of such Warrant Shares, if any. Upon delivery of an Exercise
Notice, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares.
If this Warrant is submitted in connection with any exercise pursuant to this Section 3 (b) and the number of Warrant Shares
represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise,
then, at the request of the Holder, the Company shall as soon as practicable and in no event later than three (3) Business Days
after any exercise and at its own expense, issue and deliver to the Holder (or its designee) a new Warrant (in accordance with
Section 11(d)) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise
under this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised. Fractional shares of stock
are to be issued upon the exercise of this Warrant. The Company shall pay any and all taxes and fees which may be payable with
respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant. Following the exercise in full of this Warrant,
the Holder shall deliver this original Warrant certificate to the Company. For purposes of this Warrant, “Business Day”
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required
by law to remain closed.

 

(c) Company’s
Failure to Timely Deliver Securities. If the Company shall fail for any reason or for no reason to issue to the Warrant Holder
within five (5) Business Days of receipt of the Exercise Notice so long as the Warrant Holder delivers the Aggregate Exercise
Price on or prior to the second (2nd) Business Day following the date on which the Company has received the Exercise
Notice, a certificate for the number of Warrant Shares to which the Warrant Holder is entitled and register such Warrant Shares
on the Company’s shareholder register, then, the Warrant Holder is entitled to all remedies available to him Nothing shall limit
the Warrant Holder’s right to pursue any remedies available to it hereunder, at law or in equity, including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates
representing the Warrant Shares (or to electronically deliver such Warrant Shares) upon the exercise of this Warrant as required
pursuant to the terms hereof.

 

    	 	2	 

     

    

 

(d)
Fractional Warrant Shares. Fractional Warrant Shares will be issued in connection with any exercise hereunder.

 

(e)
Legend. The Warrant Shares to be acquired by the Holder pursuant hereto, may not be sold or transferred unless (A) such
securities are sold pursuant to an effective registration statement under the Securities Act, or (B) the Company or its transfer
agent shall have been furnished with an opinion of counsel (which opinion shall be in form, substance and scope customary for
opinions of counsel in comparable transactions and from an attorney who regularly practices securities law) to the effect that
the securities to be sold or transferred may be sold or transferred pursuant to an exemption from such registration or (C) such
securities are sold or transferred pursuant to Rule 144 under the Securities Act (or a successor rule) (“Rule 144”)
or (D) such shares are sold or transferred outside the United States in accordance with Rule 904 of Regulation S under the
Securities Act, or (E) such shares are transferred to an “affiliate” (as defined in Rule 144) of the Company who agrees
to sell or otherwise transfer the shares only in accordance with this Section 3(e). Except as otherwise provided in this Warrant
(and subject to the removal provisions set forth below), until such time as the Warrant Shares issuable upon exercise of the Warrant
have been registered under the Act, otherwise may be sold pursuant to Rule 144 without any restriction as to the number of securities
as of a particular date that can then be immediately sold, each certificate for Warrant Shares that has not been so included in
an effective registration statement or that has not been sold pursuant to an effective registration statement or an exemption
that permits removal of the legend, shall bear a legend substantially in the following form, as appropriate:

 

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED. THE HOLDER
HEREOF, BY PURCHASING SUCH SECURITIES, AGREES THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY
(A) TO THE CORPORATION, (B) OUTSIDE THE UNITED STATES IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT,
(C) WITHIN THE UNITED STATES AFTER REGISTRATION OR IN ACCORDANCE WITH THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS UNDER THE
U.S. SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER, IF APPLICABLE, AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, OR
(D) WITHIN THE UNITED STATES IN A TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE U.S. SECURITIES ACT OR ANY APPLICABLE
STATE SECURITIES LAWS AND THE HOLDER HAS PRIOR TO SUCH SALE FURNISHED TO THE CORPORATION AN OPINION OF COUNSEL REASONABLY SATISFACTORY
TO THE CORPORATION.

 

    	 	3	 

     

    

 

(f) Removal
of Legend. The legend set forth above shall be removed and the Company shall issue to the Holder a new certificate
therefor free of any transfer legend if (A) the Company shall have received an opinion of counsel, in form, substance and
scope customary for opinions of counsel in comparable transactions, to the effect that a public sale or transfer of such
Securities may be made without registration under the Act and the shares are so sold or transferred, or (B) (C) in the
case of the Conversion Securities issuable upon exercise of the Warrant, such security is registered for sale by the Holder
under an effective registration statement filed under the Act or otherwise may be sold pursuant to Rule 144 without any
restriction as to the number of securities as of a particular date that can then be immediately sold. The Company shall cause
its counsel to issue a legal opinion promptly after the effective date of any registration statement under the Act
registering the resale of the Conversion Securities issuable upon exercise of the Warrant if required to effect the removal
of the legend hereunder.

 

4. Securities
Fully Paid; Reservation of Warrant Interests. All of the Warrant Shares issuable upon the exercise of the Warrant will,
upon issuance and receipt of the Warrant Price for such Warrant Shares, be duly authorized, validly issued, fully paid and non-assessable,
and will be free and clear of all taxes, liens, encumbrances and charges with respect to the issue.

 

5. Rights
of the Warrant Holder. The Warrant Holder shall have no voting rights as a member or rights to dividends or other distributions
with respect to Warrant Shares subject to this Agreement until payment in full of the Warrant Price for Warrant Shares being issued
and such securities are issued.

 

6. Adjustment
of Exercise Price and Number of Warrant Shares. The Exercise Price and the number of Warrant Shares purchasable upon any
exercise of the Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this
Section 6 if such events occur within the three year period following the Issue Date.

 

(a)
Subdivision or Combination of Ownership Shares; Equity Dividend and Interest Conversion.

 

(i) In
the event the Company should at any time or from time to time fix a record date for the determination of the holders of Ownership
Shares entitled to receive a dividend or other distribution payable in additional Ownership Shares or other securities or rights
directly or indirectly convertible into or exercisable or exchangeable, or rights that entitle the holders of Ownership Shares
to purchase, Ownership Shares (hereinafter referred to as “Ownership Share Equivalents”), without payment of
any consideration by such holders for the additional Ownership Shares or the Ownership Share Equivalents (including the additional
Ownership Shares issuable upon conversion or exercise thereof), then, as of such record date (or the date of such dividend distribution,
split or subdivision if no record date is fixed), (y) the Exercise Price of the Warrant Shares shall be appropriately decreased
or (z) the number of Warrant Shares shall be increased in proportion to such increase of outstanding Ownership Shares and Ownership
Shares issuable with respect to Ownership Share Equivalents.

 

(ii) If
the number of Ownership Shares outstanding at any time after the Issue Date is decreased by a combination of the outstanding
Ownership Shares, then, upon the record date of such combination, (A) the Exercise Price shall be appropriately increased, or
(B) the number of Warrant Shares shall be decreased in proportion to such decrease in outstanding Ownership
Shares.

 

    	 	4	 

     

    

 

(iii)
The Company will not modify its articles of organization or effect any reorganization, recapitalization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities in a manner that negates or avoids the rights of the Warrant Holder to exercise
its rights hereunder, but will at all times assist in the carrying out of all the provisions of this Agreement and in the taking
of all such actions as may be necessary or appropriate in order to protect the Warrant Holder against impairment.

 

(b) Other
Notices. In the event that the Company shall propose at any time: (i) to declare any dividend or distribution upon any
class or series of securities, whether in cash, property, stock or other securities (including, without limitation, pursuant
to a subdivision of the outstanding shares of capital stock); (ii) to effect any reclassification or recapitalization of its
Ownership Shares outstanding involving a change in such securities; or (iii) to merge or consolidate with or into any other
corporation, or to sell, lease or convey all or substantially all of its property or business, or to liquidate, dissolve or
wind up; then, in connection with each such event, the Company shall mail to the Warrant Holder notice of such
transaction:

 

(A) at
least five (5) business days’ prior written notice in accordance with Section 10 of the date on which a record shall be
taken for such dividend or distribution (and specifying the date on which the holder of the affected class or series of capital
stock shall be entitled thereto) or for determining the rights to vote, if any, in respect of the matters referred to in (c)(ii)
and (c)(iii) above; and

 

(B) in
the case of the matters referred to in (c)(ii) and (c)(iii) above, written notice of such impending transaction not later than
ten (10) business days’ prior to any shareholders’ meeting called to approve such transaction, or ten (10) business days’ prior
to the closing of such transaction, whichever is earlier, and shall also notify the Warrant Holder in writing in accordance with
Section 10 of the final approval of such transaction by the stockholders of the Company (if such approval is required).
The first of such notices shall describe the terms and conditions of the impending transaction that are material to a holder of
Ownership Shares (as determined by the Board of Directors of the Company (the “Board”) in good faith) and specify
the date on which a holder of Ownership Shares shall be entitled to exchange his, her or its Ownership Shares for securities or
other property deliverable upon the occurrence of such event) and the Company shall thereafter give such holder prompt notice
of any changes in such terms or conditions that are material to a holder of Ownership Shares (as determined by the Board in good
faith). The Company acknowledges that any record date must be set at a date that would permit the Warrant Holder effectively to
exercise its rights hereunder.

 

    	 	5	 

     

    

 

(c) Changes
in Ownership Shares. In case at any time prior to the Expiration Date, the Company shall be a party to any transaction (including,
without limitation, a merger, consolidation, sale of all or substantially all of the Company’s assets or recapitalization of its
capital stock) in which the previously outstanding Ownership Shares shall be changed into or exchanged for different securities
of the Company or other securities of another corporation or interests in a non-corporate entity or other property (including
cash) or the Company shall make a distribution on its Ownership Shares, other than regular cash dividends on its outstanding Ownership
Shares, or any combination of any of the foregoing (each such transaction being herein called the “Transaction”
and the date of consummation of the Transaction being herein called the “Consummation Date”), then as a condition
of the consummation of such Transaction, lawful and adequate provisions shall be made so that the Warrant Holder, upon the exercise
hereof at any time on or after the Consummation Date and prior to the Expiration Date, shall be entitled to receive, and this
Agreement shall thereafter represent the right to receive, in lieu of the Warrant Shares issuable upon such exercise prior to
the Consummation Date, the highest amount of securities or other property to which the Warrant Holder would actually have been
entitled as a member upon the consummation of the Transaction if the Warrant Holder had exercised the Warrant immediately prior
thereto. The provisions of this Section 6(c) shall similarly apply to successive Transactions.

 

7. Taxes.
The Warrant Holder acknowledges that upon exercise of the Warrant the Warrant Holder may be deemed to have taxable income
in respect of the Warrant and/or the Warrant Shares. The Warrant Holder acknowledges that any income or other taxes due from it
with respect to the Warrant or the Warrant Interests issuable pursuant to the Warrant shall be the Warrant Holder’s responsibility.

 

8. Reserved.

 

9. Representations
and Warranties.

 

(a)
Representations and Warranties by the Warrant Holder. The representations and warranties of the Warrant Holder set forth
in the Engagement Letter are true and correct in all material respects as of the Issue Date.

 

10. Non-circumvention.
The Company hereby covenants and agrees that the Company will not, by amendment of its articles of organization or operating
agreement, or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue
or sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be
required to protect the rights of the Holder.

 

11. Reissuance
Of Warrants.

 

(a) Transfer
of Warrant. If this Warrant is to be transferred, the Warrant Holder shall surrender this Warrant to the Company
and an opinion of counsel from an attorney regularly engaged in the practice of securities law, whereupon the Company will
forthwith issue and deliver upon the order of the Warrant Holder a new Warrant (in accordance with Section 11(d)),
registered as the Warrant Holder may request, representing the right to purchase the number of Warrant Shares being
transferred by the Warrant Holder and, if less than the total number of Warrant Shares then underlying this Warrant is being
transferred, a new Warrant (in accordance with Section 11(d)) to the Warrant Holder representing the right to purchase the
number of Warrant Shares not being transferred.

 

    	 	6	 

     

    

 

(b) Lost,
Stolen or Mutilated Warrant. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant, and, in the case of loss, theft or destruction, of any indemnification and payment
of any required bond undertaking by the Warrant Holder to the Company in customary form and, in the case of mutilation, upon surrender
and cancellation of this Warrant, the Company shall execute and deliver to the Warrant Holder a new Warrant (in accordance with
Section 11(d)) representing the right to purchase the Warrant Shares then underlying this Warrant.

 

(c) Exchangeable
for Multiple Warrants. This Warrant is exchangeable, upon the surrender hereof by the Warrant Holder at the principal office
of the Company, for a new Warrant or Warrants (in accordance with Section 11(d)) representing in the aggregate the right to purchase
the number of Warrant Shares then underlying this Warrant, and each such new Warrant will represent the right to purchase such
portion of such Warrant Shares as is designated by the Warrant Holder at the time of such surrender.

 

(d) Issuance
of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
(i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to
purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Section 11(a)
or Section 11(c), the Warrant Shares designated by the Warrant Holder which, when added to the number of Conversion Securities
underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying
this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance
Date, and (iv) shall have the same rights and conditions as this Warrant.

 

12. Amendment
And Waiver. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained
the written consent of the Warrant Holder.

 

13. Dispute
Resolution.

 

(a) This
Warrant shall be governed by, and construed in accordance with, the internal laws of the State of Florida without regard to
the choice of law principles thereof. Each of the parties of the Warrant hereto irrevocably submits to the exclusive
jurisdiction of the courts of the State of Florida located in Dade County and the United States District Court for the
Southern District of Florida in Miami for the purpose of any suit, action, proceeding or judgment relating to or arising out
of this Warrant. Service of process in connection with any such suit, action or proceeding may be served on each party hereto
anywhere in the world by the same methods as are specified for the giving of notices under the Subscription Agreement. Each
of the parties of this Warrant irrevocably consents to the jurisdiction of any such court in any such suit, action or
proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying
of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any claim that any such suit,
action or proceeding brought in any such court has been brought in an inconvenient forum. EACH OF THE PARTIES HERETO
WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS WARRANT AND REPRESENTS THAT COUNSEL HAS
BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.

 

    	 	7	 

     

    

 

(b) Each
party shall bear its own expenses in any litigation conducted under this section.

 

(c)
The Company consents to accept service of process by the certified mail, return receipt requested in the event of litigation.
The Company further consents to accept service of process via recognized international courier in the case that the Company
is not able to accept service by the certified mail provideda receipt of delivery is available.

 

14. Remedies,
Other Obligations, Breaches And Injunctive Relief. The remedies provided in this Warrant shall be cumulative and in
addition to all other remedies available under this Warrant and the Subscription Agreement, at law or in equity (including a
decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Warrant
Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company
acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Warrant Holder and that the
remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or
threatened breach, the holder of this Warrant shall be entitled, in addition to all other available remedies, to an
injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security
being required. The Company shall provide all information and documentation to the Warrant Holder that is requested by the
Holder to enable the Holder to confirm the Company’s compliance with the terms and conditions of this Warrant (including,
without limitation, compliance with Section 6 hereof).

 

15. Transfer.
This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company.

 

16. Severability.
If any provision of this Warrant is prohibited by law or otherwise determined to be invalid or unenforceable by a court of
competent jurisdiction, the provision that would otherwise be prohibited, invalid or unenforceable shall be deemed amended to
apply to the broadest extent that it would be valid and enforceable, and the invalidity or unenforceability of such provision
shall not affect the validity of the remaining provisions of this Warrant so long as this Warrant as so modified continues to
express, without material change, the original intentions of the parties as to the subject matter hereof and the prohibited nature,
invalidity or unenforceability of the provision(s) in question does not substantially impair the respective expectations or reciprocal
obligations of the parties or the practical realization of the benefits that would otherwise be conferred upon the parties. The
parties will endeavor in good faith negotiations to replace the prohibited, invalid or unenforceable provision(s) with a valid
provision(s), the effect of which comes as close as possible to that of the prohibited, invalid or unenforceable provision(s).

 

    	 	8	 

     

    

 

17.
Assignability. Notwithstanding anything contained
herein to the contrary, subject to the transfer and securities law restrictions set forth in this Agreement, the Warrant Holder
may assign, convey or transfer, in whole or in part, its rights under this Agreement and provide written notice to Company of
any such assignment, conveyance or transfer. Upon any transfer, assignment, pledge, hypothecation or other disposition of the
Warrant or of any rights granted hereunder in accordance with the terms of this Section 17, the Company shall if necessary
issue or re-issue warrant agreements reflecting the appropriate rights and entitlements of the Warrant Holder and any transferee,
assignee or pledgee after giving effect to such transfer, assignment or pledge.

 

18. Notice.
Any notice to be provided hereunder, unless otherwise herein specified, shall be provided in the manner set forth in the Engagement
Letter.

 

[signatures
on following page]

 

    	 	9	 

     

    

 

IN WITNESS WHEREOF,
the undersigned hereby execute this Agreement as of the day and year first above written.

 

	 	COMPANY:
	 	 	 
	 	HEALTHLYNKED CORPORATION
	 	 	 
	 	By:	/s/
    George o’Leary
	 	Name:	George o’Leary
	 	Title:	CFO
	 	 	 
	 	WARRANT HOLDER:
	 	 	 
	 	DELANEY EQUITY GROUP, LLC
	 	 	 
	 	By:	/s/
    John Calabria
	 	Name:	John Calabria
	 	Title:	Banking Group

 

[Signature
Page - Warrant Agreement]

    	 	10	 

     

    

 

EXHIBIT
A

 

NOTICE
OF EXERCISE

 

The
undersigned holder hereby exercises the right to purchase ___________________ shares of (“Warrant Shares”) of
HealthLynked Corporation, a Nevada Corporation (the “Company”), evidenced by the attached Warrant No. 2
(the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings
set forth in the Warrant.

 

1. Form
of Exercise Price. The Warrant Holder intends that payment of the Exercise Price shall be made as:

 

	                           	 	a “Cash Exercise” with respect to                                                      Warrant
    Shares.

 

2. Payment
of Exercise Price. The holder shall pay the Aggregate Exercise Price in the sum of $___________ to the Company in
accordance with the terms of the Warrant,

 

3.
Delivery of Warrant Shares. The Company shall deliver to the holder____________ Warrant Shares in accordance with the terms
of the Warrant.

 

Date:_______________ ,         

 

	 	 	 
	Name of Registered Holder 	 	 

 

	DELANEY EQUITY GROUP, LLC	 
	 	 	 
	By:		 
	Name:	John Calabria	 
	Title:	Banking GroupExhibit 10.7

 

EXECUTION
COPY

 

INVESTMENT
AGREEMENT

 

This
INVESTMENT AGREEMENT (the “Agreement”), dated as of July 11 2016 (the “Execution Date”),
is entered into by and between HealthLynked Corp. (the “Company”), a Nevada corporation, with its principal
executive offices at 1726 Medical Blvd Suite 101 Naples, FL 34110, and Iconic Holdings, LLC (the “Investor”),
a Delaware limited liability company, with its principal executive offices at 2251 San Diego Ave, #B150, San Diego, CA 92110.

 

RECITALS:

 

WHEREAS,
the parties desire that, upon the terms and subject to the conditions contained herein, the Investor shall invest up to Three
Million Dollars ($3,000,000) (the “Commitment Amount”) to purchase the Company’s common stock, par value of
$.0001 per share (the “Common Stock”);

 

WHEREAS,
such investments will be made in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities
Act of 1933, as amended (the “1933 Act”), Rule 506 of Regulation D promulgated by the SEC under the 1933 Act,
and/or upon such other exemption from the registration requirements of the 1933 Act as may be available with respect to any or
all of the investments in Common Stock to be made hereunder; and

 

WHEREAS,
contemporaneously with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration
Rights Agreement substantially in the form attached hereto as Exhibit A (the “Registration Rights Agreement”)
pursuant to which the Company has agreed to provide certain registration rights under the 1933 Act, and the rules and regulations
promulgated thereunder, and applicable state securities laws.

 

NOW
THEREFORE, in consideration of the foregoing recitals, which shall be considered an integral part of this Agreement, the covenants
and agreements set forth hereafter, and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Company and the Investor hereby agree as follows:

 

SECTION
I.

DEFINITIONS

 

For
all purposes of and under this Agreement, the following terms shall have the respective meanings below, and such meanings shall
be equally applicable to the singular and plural forms of such defined terms.

 

“1933
Act” shall have the meaning set forth in the recitals.

 

“1934
Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar federal statute, and the rules and regulations
of the SEC thereunder, all as the same will then be in effect.

 

“Affiliate”
means any individual or entity that, directly or indirectly through one or more intermediaries, controls or is controlled by or
is under common control with another individual or entity as such terms are used in and construed under Rule 405 under the 1933
Act.

 

    

     

    

 

“Agreement”
shall have the meaning set forth in the preamble.

 

“Articles
of Incorporation” shall have the meaning set forth in Section 4.3.

 

“By-laws”
shall have the meaning set forth in Section 4.3.

 

“Certificate”
shall have the meaning set forth in Section 2.5.

 

“Closing”
shall have the meaning set forth in Section 2.5.

 

“Closing
Date” shall have the meaning set forth in Section 2.5.

 

“Commitment
Fee Note” shall have the meaning set forth in Section 10.17

 

“Commitment
Amount” shall have the meaning set forth in the recitals.

 

“Common
Stock” shall have the meaning set forth in the recitals.

 

“Company”
shall have the meaning set forth in the preamble.

 

“DTC”
shall have the meaning set forth in Section 2.5.

 

“DWAC”
shall mean Deposit and Withdrawal at Custodian service provided by the Depository Trust Company.

 

“Effective
Date” shall mean the date the SEC declares effective under the 1933 Act the Registration Statement covering the Securities.

 

“Environmental
Laws” shall have the meaning set forth in Section 4.13.

 

“Execution
Date” shall have the meaning set forth in the preamble.

 

“FAST”
shall have the meaning set forth in Section 2.5.

 

“Investor”
shall have the meaning set forth in the preamble.

 

“Material
Adverse Effect” shall have the meaning set forth in Section 4.1.

 

“Maximum
Common Stock Issuance” shall have the meaning set forth in Section 2.6.

 

“Open
Period” shall mean the period beginning on and including the Trading Day immediately following the Effective Date and
ending on the earlier to occur of (i) the date which is thirty-six (36) months from the Effective Date; or (ii) termination of
the Agreement in accordance with Section 8.

 

“PCAOB”
shall have the meaning set forth in Section 4.6.

 

“Pricing
Period” shall mean, with respect to a particular Put Notice, the five (5) consecutive Trading Days including and immediately
following the applicable Put Notice Date.

 

    	 	- 2 -	 

     

    

 

“Principal
Market” shall mean the New York Stock Exchange, the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market, the OTC Bulletin Board or the OTC Markets Group, whichever is the principal market on which the Common
Stock is traded.

 

“Purchase
Amount” shall mean the total amount being paid by the Investor on a particular Closing Date to purchase the Securities,
calculated by multiplying the Purchase Price by the Put Amount.

 

“Purchase
Price” shall mean the 80% of the lowest volume weighted average price of the Common Stock during the Pricing Period
applicable to the Put Notice, provided, however, an additional 5% will be added to the discount of each Put if (i) the Company
is not DWAC eligible and (ii) an additional 10% will be added to the discount of each Put if the Company is under DTC “chill”
status on the applicable Put Notice Date and in the case of both, the discount shall be a cumulative increase to the discount
will be 15%, i.e., from 80% to 65%

 

“Put”
shall have the meaning set forth in Section 2.2.

 

“Put
Amount” shall have the meaning set forth in Section 2.3.

 

“Put
Notice” shall mean a written notice sent to the Investor by the Company stating the Put Amount in U.S. dollars that
the Company intends to sell to the Investor pursuant to the terms of the Agreement and stating the current number of Shares issued
and outstanding on such date.

 

“Put
Notice Date” shall mean the Trading Day on which the Investor receives a Put Notice, determined as follows: a Put Notice
shall be deemed delivered on (a) the Trading Day it is received by electronic mail or otherwise by the Investor if such notice
is received prior to 9:30 a.m. (Pacific time), or (b) the immediately succeeding Trading Day if it is received by electronic mail
or otherwise after 9:30 a.m. (Pacific time) on a Trading Day. No Put Notice may be deemed delivered on a day that is not a Trading
Day.

 

“Put
Settlement Sheet” shall mean a written letter to the Company by the Investor, evidencing acceptance of the Put and providing
instructions for delivery of the Securities to the Investor.

 

“Put
Shares Due” shall mean the Shares to be sold to the Investor pursuant to the Put.

 

“Registered
Offering Transaction Documents” shall mean this Agreement and the Registration Rights Agreement between the Company
and the Investor as of the date herewith.

 

“Registration
Rights Agreement” shall have the meaning set forth in the recitals.

 

“Registration
Statement” means the registration statement of the Company filed under the 1933 Act covering the resale of the Securities
issuable hereunder by the Investor, in the manner described in such Registration Statement.

 

“Resolutions”
shall have the meaning set forth in Section 7.5.

 

“SEC”
shall mean the U.S. Securities and Exchange Commission.

 

“SEC
Documents” shall have the meaning set forth in Section 4.6.

 

    	 	- 3 -	 

     

    

 

“Securities”
shall mean the shares of Common Stock issued pursuant to the terms of the Agreement.

 

“Shares”
shall mean the shares of the Company’s Common Stock.

 

“Subsidiaries”
shall have the meaning set forth in Section 4.1.

 

“Trading
Day” shall mean any day on which the Principal Market for the Common Stock is open for trading, from the hours of 9:30
am until 4:00 pm.

 

“VWAP”
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then
listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the Trading Market on which the Common Stock is then listed or quoted for trading as reported by (i) Bloomberg
Financial L.P. or (ii) Stock Charts/Quote Media if the Investor does not promptly provide the Company the Bloomberg quote/pricing
charts for the days involved upon the Company’s request (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02
p.m. (New York City time)) and (b) in all other cases, the fair market value of a share of Common Stock as determined by an independent
appraiser selected in good faith by the Investor and the Company.

 

“Waiting
Period” shall have the meaning set forth in Section 2.3.

 

“Warrants”
shall have the meaning set forth in Section 10.18.

 

SECTION
II

PURCHASE
AND SALE OF COMMON STOCK

 

2.1       PURCHASE
AND SALE OF COMMON STOCK. Subject to the terms and conditions set forth herein, the Company shall issue and sell to the Investor,
and the Investor shall purchase from the Company, up to that number of Shares having an aggregate Purchase Price of Three Million
Dollars ($3,000,000).

 

2.2       DELIVERY
OF PUT NOTICES. Subject to the terms and conditions of the Registered Offering Transaction Documents, and from time to time
during the Open Period, the Company may, in its sole discretion, deliver a Put Notice to the Investor which states the share amount
(designated in whole shares of the Company’s Common Stock), which the Company intends to sell to the Investor on a Closing
Date (the “Put”). The Put Notice shall be in the form attached hereto as Exhibit B and incorporated
herein by reference. Upon receipt of the Put Notice, the Investor shall deliver to the Company a Put Settlement Sheet on the Put
Notice Date. The Put Settlement Sheet shall be in the form attached hereto as Exhibit C and incorporated herein by reference.

 

2.3       PUT
FORMULA. The maximum amount that the Company shall be entitled to Put to the Investor per any applicable Put Notice an amount
of shares of Common Stock up to or equal to one hundred percent (100%) of the average of the daily trading volume (U.S. market
only) of the Common Stock for the ten (10) consecutive Trading Days immediately prior to the applicable Put Notice Date (the “Put
Amount”) so long as such amount is at least $5,000 and does not exceed $150,000, as calculated by multiplying the Put
Amount by the average daily VWAP for the ten (10) consecutive Trading Days immediately prior to the applicable Put Notice Date.
During the Open Period, the Company shall not be entitled to submit a Put Notice until after the previous Closing has been completed.
Notwithstanding the foregoing, the Company may not deliver a Put Notice on or earlier of the tenth (10th) Trading Day
immediately following the preceding Put Notice Date (the “Waiting Period”).

 

    	 	- 4 -	 

     

    

 

2.4       CONDITIONS
TO INVESTOR’S OBLIGATION TO PURCHASE SHARES. Notwithstanding anything to the contrary in this Agreement, the Company
shall not be entitled to deliver a Put Notice and the Investor shall not be obligated to purchase any Shares at a Closing unless
each of the following conditions are satisfied:

 

		i.	a
                                         Registration Statement shall have been declared effective and shall remain effective
                                         and available for the resale of all the Put Shares Due at all times until the Closing
                                         with respect to the applicable Put Notice;

 

		ii.	at
                                         all times during the period beginning on the related Put Notice Date and ending on and
                                         including the related Closing Date, the Common Stock shall have been listed or quoted
                                         for trading on the Principal Market and shall not have been suspended from trading thereon
                                         during the Pricing Period;

 

		iii.	the
                                         Company has complied with its obligations and is otherwise not in material breach of
                                         or in material default under, this Agreement, the Registration Rights Agreement or any
                                         other agreement executed in connection herewith which has not been cured prior to delivery
                                         to the Investor of the applicable Put Notice;

 

		iv.	no
                                         injunction shall have been issued and remain in force, or action commenced by a governmental
                                         authority which has not been stayed or abandoned, prohibiting the purchase or the issuance
                                         of the Securities; and

 

		v.	the
                                         issuance of the Securities will not violate any shareholder approval requirements of
                                         the Principal Market.

 

If
any of the events described in clauses (i) through (v) above occurs during a Pricing Period, then the Investor shall have no obligation
to purchase the Put Amount of Common Stock set forth in the applicable Put Notice.

 

2.5       MECHANICS
OF PURCHASE OF SHARES BY INVESTOR. Subject to the satisfaction of the conditions set forth in Sections 2.6 and 7 of
this Agreement, the closing of the purchase by the Investor of Securities (a “Closing”) shall occur on the
date which is no earlier than five (5) Trading Days following and no later than seven (7) Trading Days following the applicable
Put Notice Date (each a “Closing Date”). On each such Closing Date, if the Company’s transfer agent is
participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer (“FAST”)
program and that the Securities are eligible for inclusion in the FAST program, the Company shall use all commercially reasonable
efforts to cause its transfer agent to electronically transmit the Securities to be issued to the Investor on such date by crediting
the account of the Investor’s prime broker (as specified by the Investor in a Put Settlement Sheet) with DTC through its
DWAC service. If the Company is not DWAC eligible or the Company is under DTC “chill” on such Closing Date, the Company
shall deliver to the Investor pursuant to this Agreement, certificates representing the Securities to be issued to the Investor
on such date and registered in the name of the Investor (the “Certificate”). On such Closing Date, after receipt
of confirmation of delivery of such Securities to the Investor, the Investor shall disburse the funds constituting the Purchase
Amount to the Company’s designated account by wire transfer of (i) immediately available funds if the Investor receives
the Securities by 9:30 a.m. (Pacific time) or (ii) next day available funds if the Investor receives the Securities thereafter.

 

    	 	- 5 -	 

     

    

 

2.6       OVERALL
LIMIT ON COMMON STOCK ISSUABLE. Notwithstanding anything contained herein to the contrary, if during the Open Period the Company
becomes listed on an exchange that limits the number of shares of Common Stock that may be issued without shareholder approval,
then the number of Shares issuable by the Company and purchasable by the Investor, shall not exceed that number of the shares
of Common Stock that may be issuable without shareholder approval (the “Maximum Common Stock Issuance”). If
such issuance of shares of Common Stock could cause a delisting on the Principal Market, then the Maximum Common Stock Issuance
shall first be approved by the Company’s shareholders in accordance with applicable law and the By-laws and the Articles
of Incorporation of the Company, if such issuance of shares of Common Stock could cause a delisting on the Principal Market. The
parties understand and agree that the Company’s failure to seek or obtain such shareholder approval shall in no way adversely
affect the validity and due authorization of the issuance and sale of Securities or the Investor’s obligation in accordance
with the terms and conditions hereof to purchase a number of Shares in the aggregate up to the Maximum Common Stock Issuance limitation,
and that such approval pertains only to the applicability of the Maximum Common Stock Issuance limitation provided in this Section
2.6.

 

2.7       LIMITATION
ON AMOUNT OF OWNERSHIP. Notwithstanding anything to the contrary in this Agreement, in no event shall the Investor be entitled
to purchase that number of Shares, which when added to the sum of the number of shares of Common Stock beneficially owned (as
such term is defined under Section 13(d) and Rule 13d-3 of the 1934 Act), by the Investor, would exceed 9.99% of the number of
shares of Common Stock outstanding on the Closing Date, as determined in accordance with Rule 13d-1(j) of the 1934 Act.

 

SECTION
III

INVESTOR’S
REPRESENTATIONS, WARRANTIES AND COVENANTS

 

The
Investor represents and warrants to the Company, and covenants, that:

 

3.1       SOPHISTICATED
INVESTOR. The Investor has, by reason of its business and financial experience, such knowledge, sophistication and experience
in financial and business matters and in making investment decisions of this type that it is capable of (i) evaluating the merits
and risks of an investment in the Securities and making an informed investment decision; (ii) protecting its own interest; and
(iii) bearing the economic risk of such investment for an indefinite period of time.

 

3.2       AUTHORIZATION;
ENFORCEMENT. This Agreement has been duly and validly authorized, executed and delivered on behalf of the Investor and is
a valid and binding agreement of the Investor enforceable against the Investor in accordance with its terms, subject as to enforceability
to general principles of equity and to applicable bankruptcy, insolvency, reorganization, moratorium, liquidation and other similar
laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies.

 

3.3       SECTION
9 OF THE 1934 ACT. During the term of this Agreement, the Investor will comply with the provisions of Section 9 of the 1934
Act, and the rules promulgated thereunder, with respect to transactions involving the Common Stock. During the term of this Agreement,
including without limitation any time after the “Effective Date,” the Investor, and its control persons, affiliates,
principals and advisors, and any other person or entity acting by, through or in conjunction with any of them, shall not conduct
or participate in any short selling or hedging of the Company’s common stock that is the subject of this Agreement or the
Registration Rights Agreement.

 

    	 	- 6 -	 

     

    

 

3.4       ACCREDITED
INVESTOR. The Investor is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D of the
1933 Act.

 

3.5       NO
CONFLICTS. The execution, delivery and performance of the Registered Offering Transaction Documents by the Investor and the
consummation by the Investor of the transactions contemplated hereby and thereby will not result in a violation of limited liability
company agreement or other organizational documents of the Investor.

 

3.6       OPPORTUNITY
TO DISCUSS. The Investor has received all materials relating to the Company’s business, finance and operations which
it has requested. The Investor has had an opportunity to discuss the business, management and financial affairs of the Company
with the Company’s management.

 

3.7       INVESTMENT
PURPOSES. The Investor is purchasing the Securities for its own account for investment purposes and not with a view towards
distribution and agrees to resell or otherwise dispose of the Securities solely in accordance with the registration provisions
of the 1933 Act (or pursuant to an exemption from such registration provisions).

 

3.8       NO
REGISTRATION AS A DEALER. The Investor is not and will not be required to be registered as a “dealer” under the
1934 Act, either as a result of its execution and performance of its obligations under this Agreement or otherwise.

 

3.9       GOOD
STANDING. The Investor is a limited liability company, duly organized, validly existing and in good standing in the State
of Delaware.

 

3.10     TAX
LIABILITIES. The Investor understands that it is liable for its own tax liabilities.

 

3.11     REGULATION
M. The Investor will comply with Regulation M under the 1934 Act, if applicable.

 

3.12     General
Solicitation. The Investor is not purchasing the Securities as a result of any advertisement, article, notice or other
communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio
or presented at any seminar or any other general solicitation or general advertisement.

 

3.13     TRANSFER
RESTRICTIONS. The Securities may only be disposed of in compliance with federal and state securities laws. In connection with
any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an affiliate
of the Investor, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the
transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory
to the Company, to the effect that such transfer does not require registration of such transferred Securities under the 1933 Act;
provided, however, that in connection with any transfer of Securities pursuant to Rule 144, the Company may require the transferor
to provide a customary Rule 144 sellers representation letter. As a condition of transfer, any such transferee shall agree in
writing to be bound by the terms of this Agreement and shall have the rights of the Investor under this Agreement and the Registration
Rights Agreement, as to issued Securities only.

 

    	 	- 7 -	 

     

    

 

SECTION
IV

REPRESENTATIONS
AND WARRANTIES OF THE COMPANY

 

Except
as set forth in the Schedules attached hereto, the Company represents and warrants to the Investor that:

 

4.1       ORGANIZATION
AND QUALIFICATION. The Company is a corporation duly organized and validly existing in good standing under the laws of the
State of Nevada, and has the requisite corporate power and authorization to own its properties and to carry on its business as
now being conducted. Both the Company and the companies it owns or controls (“Subsidiaries”) are duly qualified
to do business and are in good standing in every jurisdiction in which its ownership of property or the nature of the business
conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing
would not have a Material Adverse Effect. As used in this Agreement, “Material Adverse Effect” means a change,
event, circumstance, effect or state of facts that has had or is reasonably likely to have, a material adverse effect on the business,
properties, assets, operations, results of operations, financial condition or prospects of the Company and its Subsidiaries, if
any, taken as a whole, or on the transactions contemplated hereby or by the agreements and instruments to be entered into in connection
herewith, or on the authority or ability of the Company to perform its obligations under the Registered Offering Transaction Documents.

 

4.2       AUTHORIZATION;
ENFORCEMENT; COMPLIANCE WITH OTHER INSTRUMENTS.

 

		i.	The
                                         Company has the requisite corporate power and authority to enter into and perform the
                                         Registered Offering Transaction Documents, and to issue the Securities in accordance
                                         with the terms hereof and thereof.

 

		ii.	The
                                         execution and delivery of the Registered Offering Transaction Documents by the Company
                                         and the consummation by it of the transactions contemplated hereby and thereby, including
                                         without limitation the issuance of the Securities pursuant to this Agreement, have been
                                         duly and validly authorized by the Company’s board of directors and no further
                                         consent or authorization is required by the Company, its board of directors, or its shareholders.

 

		iii.	The
                                         Registered Offering Transaction Documents have been duly and validly executed and delivered
                                         by the Company.

 

		iv.	The
                                         Registered Offering Transaction Documents constitute the valid and binding obligations
                                         of the Company enforceable against the Company in accordance with their terms, except
                                         as such enforceability may be limited by general principles of equity or applicable bankruptcy,
                                         insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting
                                         generally, the enforcement of creditors’ rights and remedies.

 

4.3       CAPITALIZATION.
As of the date hereof, the authorized capital stock of the Company consists of (i) 230,000,000 shares of the Common Stock, par
value $.0001 per share, of which 62,612,500 were issued and outstanding as of June 27, 2016, and (ii) 20,000,000 shares of preferred
stock, par value $.0001 per share, of which 2,953,840 are designated as Series A Convertible Preferred Stock and are issued and
outstanding as of June 27, 2016. All of such outstanding shares have been, or upon issuance will be, validly issued and are fully
paid and non-assessable.

 

    	 	- 8 -	 

     

    

 

Except
as disclosed in the Company’s publicly available filings with the SEC or as otherwise set forth on Schedule 4.3:

 

		i.	no
                                         shares of the Company’s capital stock are subject to preemptive rights or any other
                                         similar rights or any liens or encumbrances suffered or permitted by the Company;

 

		ii.	there
                                         are no outstanding debt securities;

 

		iii.	there
                                         are no outstanding shares of capital stock, options, warrants, scrip, rights to subscribe
                                         to, calls or commitments of any character whatsoever relating to, or securities or rights
                                         convertible into, any shares of capital stock of the Company or any of its Subsidiaries,
                                         or contracts, commitments, understandings or arrangements by which the Company or any
                                         of its Subsidiaries is or may become bound to issue additional shares of capital stock
                                         of the Company or any of its Subsidiaries or options, warrants, scrip, rights to subscribe
                                         to, calls or commitments of any character whatsoever relating to, or securities or rights
                                         convertible into, any shares of capital stock of the Company or any of its Subsidiaries;

 

		iv.	there
                                         are no agreements or arrangements under which the Company or any of its Subsidiaries
                                         is obligated to register the sale of any of their securities under the 1933 Act (except
                                         the Registration Rights Agreement);

 

		v.	there
                                         are no outstanding securities of the Company or any of its Subsidiaries which contain
                                         any redemption or similar provisions, and there are no contracts, commitments, understandings
                                         or arrangements by which the Company or any of its Subsidiaries is or may become bound
                                         to redeem a security of the Company or any of its Subsidiaries;

 

		vi.	there
                                         are no securities or instruments containing anti-dilution or similar provisions that
                                         will be triggered by the issuance of the Securities as described in this Agreement;

 

		vii.	the
                                         Company does not have any stock appreciation rights or “phantom stock” plans
                                         or agreements or any similar plan or agreement; and

 

		viii.	there
                                         is no dispute as to the classification of any shares of the Company’s capital stock.

 

The
Company has furnished to the Investor, or the Investor has had access through EDGAR to, true and correct copies of the Company’s
Articles of Incorporation, as in effect on the date hereof (the “Articles of Incorporation”), and the Company’s
By-laws, as in effect on the date hereof (the “By-laws”), and the terms of all securities convertible into
or exercisable for Common Stock and the material rights of the holders thereof in respect thereto.

 

4.4       ISSUANCE
OF SHARES. As of the Effective Date, the Company will have reserved the amount of Shares included in the Registration Statement
for issuance pursuant to the Registered Offering Transaction Documents, which will have been duly authorized and reserved (subject
to adjustment pursuant to the Company’s covenant set forth in Section 5.5 below) pursuant to this Agreement. Upon
issuance in accordance with this Agreement, the Securities will be validly issued, fully paid for and non-assessable and free
from all taxes, liens and charges with respect to the issuance thereof. In the event the Company cannot reserve a sufficient number
of Shares for issuance pursuant to this Agreement, the Company will use its best efforts to authorize and reserve for issuance
the number of Shares required for the Company to perform its obligations hereunder as soon as reasonably practicable.

 

    	 	- 9 -	 

     

    

 

4.5       NO
CONFLICTS. The execution, delivery and performance of the Registered Offering Transaction Documents by the Company and the
consummation by the Company of the transactions contemplated hereby and thereby will not (i) result in a violation of the Articles
of Incorporation or the By-laws; or (ii) conflict with, or constitute a material default (or an event which with notice or lapse
of time or both would become a material default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any material agreement, contract, indenture mortgage, indebtedness or instrument to which the Company or any
of its Subsidiaries is a party, or to the Company’s knowledge result in a violation of any law, rule, regulation, order,
judgment or decree (including United States federal and state securities laws and regulations and the rules and regulations of
the Principal Market or principal securities exchange or trading market on which the Common Stock is traded or listed) applicable
to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound
or affected. Neither the Company nor its Subsidiaries is in violation of any term of, or in default under, the Articles of Incorporation
or the By-laws or their organizational charter or by-laws, respectively, or any contract, agreement, mortgage, indebtedness, indenture,
instrument, judgment, decree or order or any statute, rule or regulation applicable to the Company or its Subsidiaries, except
for possible conflicts, defaults, terminations, amendments, accelerations, cancellations and violations that would not individually
or in the aggregate have or constitute a Material Adverse Effect. The business of the Company and its Subsidiaries is not being
conducted, and shall not be conducted, in violation of any law, statute, ordinance, rule, order or regulation of any governmental
authority or agency, regulatory or self-regulatory agency, or court, except for possible violations the sanctions for which either
individually or in the aggregate would not have a Material Adverse Effect. Except as specifically contemplated by this Agreement
and as required under the 1933 Act or any securities laws of any states, to the Company’s knowledge, the Company is not
required to obtain any consent, authorization, permit or order of, or make any filing or registration (except the filing of a
registration statement as outlined in the Registration Rights Agreement between the parties) with, any court, governmental authority
or agency, regulatory or self-regulatory agency or other third party in order for it to execute, deliver or perform any of its
obligations under, or contemplated by, the Registered Offering Transaction Documents in accordance with the terms hereof or thereof.
All consents, authorizations, permits, orders, filings and registrations which the Company is required to obtain pursuant to the
preceding sentence have been obtained or effected on or prior to the date hereof and are in full force and effect as of the date
hereof. The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.
The Company is not, and will not be, in violation of the listing requirements of the Principal Market as in effect on the date
hereof and on each of the Closing Dates and is not aware of any facts which would reasonably lead to delisting of the Common Stock
by the Principal Market in the foreseeable future.

 

4.6       FINANCIAL
STATEMENTS. The financial statements of the Company for the years ending December 31, 2015 and 2014 provided to the Investor
complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of
the SEC with respect thereto. Such financial statements have been prepared in accordance with generally accepted accounting principles,
consistently applied, during the periods involved (except (i) as may be otherwise indicated in such financial statements or the
notes thereto, or (ii) to the extent they may exclude footnotes or may be condensed or summary statements) and fairly present
in all material respects the financial position of the Company as of the dates thereof and the results of its operations and cash
flows for the periods then ended (subject, in the case of unaudited statements, to normal year-end audit adjustments). No other
written information provided by or on behalf of the Company to the Investor which is not included in the SEC Documents, including,
without limitation, information referred to in Section 4.3 of this Agreement, contains any untrue statement of a material
fact or omits to state any material fact necessary to make the statements therein, in the light of the circumstance under which
they are or were made, not misleading.

 

    	 	- 10 -	 

     

    

 

4.7       ABSENCE
OF CERTAIN CHANGES. Except as set forth in Schedule 4.7, the Company does not intend to change the business operations of
the Company in any material way. The Company has not taken any steps, and does not currently expect to take any steps, to seek
protection pursuant to any bankruptcy law nor does the Company or its Subsidiaries have any knowledge or reason to believe that
its creditors intend to initiate involuntary bankruptcy proceedings.

 

4.8       ABSENCE
OF LITIGATION AND/OR REGULATORY PROCEEDINGS. There is no action, suit, proceeding, inquiry or investigation before or by any
court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers
of Company or any of its Subsidiaries, threatened against or affecting the Company, the Common Stock or any of the Company’s
Subsidiaries or any of the Company’s or the Company’s Subsidiaries’ officers or directors in their capacities
as such, in which an adverse decision could have a Material Adverse Effect.

 

4.9       ACKNOWLEDGMENT
REGARDING INVESTOR’S PURCHASE OF SHARES. The Company acknowledges and agrees that the Investor is acting solely in the
capacity of an arm’s length purchaser with respect to the Registered Offering Transaction Documents and the transactions
contemplated hereby and thereby. The Company further acknowledges that the Investor is not acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to the Registered Offering Transaction Documents and the transactions
contemplated hereby and thereby and any advice given by the Investor or any of its respective representatives or agents in connection
with the Registered Offering Transaction Documents and the transactions contemplated hereby and thereby is merely incidental to
the Investor’s purchase of the Securities, and is not being relied on by the Company. The Company further represents to
the Investor that the Company’s decision to enter into the Registered Offering Transaction Documents has been based solely
on the independent evaluation by the Company and its representatives.

 

4.10     NO
UNDISCLOSED EVENTS, LIABILITIES, DEVELOPMENTS OR CIRCUMSTANCES. As of the date hereof, no event, liability, development or
circumstance has occurred or exists, or to the Company’s knowledge is contemplated to occur, with respect to the Company
or its Subsidiaries or their respective business, properties, assets, prospects, operations or financial condition, that would
result in a Material Adverse Effect.

 

4.11     EMPLOYEE
RELATIONS. Neither the Company nor any of its Subsidiaries is involved in any union labor dispute nor, to the knowledge of
the Company or any of its Subsidiaries, is any such dispute threatened. Neither the Company nor any of its Subsidiaries is a party
to a collective bargaining agreement, and the Company and its Subsidiaries believe that relations with their employees are good.
No executive officer (as defined in Rule 501(f) of the 1933 Act) has notified the Company that such officer intends to leave the
Company’s employ or otherwise terminate such officer’s employment with the Company.

 

    	 	- 11 -	 

     

    

 

4.12     INTELLECTUAL
PROPERTY RIGHTS. The Company and its Subsidiaries own or possess adequate rights or licenses to use all trademarks, trade
names, service marks, service mark registrations, service names, patents, patent rights, copyrights, inventions, licenses, approvals,
governmental authorizations, trade secrets and rights necessary to conduct their respective businesses as now conducted. None
of the Company’s trademarks, trade names, service marks, service mark registrations, service names, patents, patent rights,
copyrights, inventions, licenses, approvals, government authorizations, trade secrets or other intellectual property rights necessary
to conduct its business as now or as proposed to be conducted have expired or terminated, or are expected to expire or terminate
within two (2) years from the date of this Agreement. The Company and its Subsidiaries do not have any knowledge of any infringement
by the Company or its Subsidiaries of trademark, trade name rights, patents, patent rights, copyrights, inventions, licenses,
service names, service marks, service mark registrations, trade secret or other similar rights of others, or of any such development
of similar or identical trade secrets or technical information by others and, , there is no claim, action or proceeding being
made or brought against, or to the Company’s knowledge, being threatened against, the Company or its Subsidiaries regarding
trademark, trade name, patents, patent rights, invention, copyright, license, service names, service marks, service mark registrations,
trade secret or other infringement; and the Company and its Subsidiaries are unaware of any facts or circumstances which might
give rise to any of the foregoing. The Company and its Subsidiaries have taken commercially reasonable security measures to protect
the secrecy, confidentiality and value of all of their intellectual properties.

 

4.13     ENVIRONMENTAL
LAWS. The Company and its Subsidiaries (i) are, to the knowledge of the management and directors of the Company and its Subsidiaries,
in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of
human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental
Laws”); (ii) have, to the knowledge of the management and directors of the Company, received all permits, licenses or
other approvals required of them under applicable Environmental Laws to conduct their respective businesses as currently conducted;
and (iii) are in compliance, to the knowledge of the management and directors of the Company, with all terms and conditions of
any such permit, license or approval where, in each of the three (3) foregoing cases, the failure to so comply would have, individually
or in the aggregate, a Material Adverse Effect.

 

4.14    TITLE.
The Company and its Subsidiaries have good and marketable title to all personal property owned by them which is material to the
business of the Company and its Subsidiaries, in each case free and clear of all liens, encumbrances and defects except such as
described in Schedule 4.14 or such as do not materially affect the value of such property and do not interfere with the use made
and proposed to be made of such property by the Company or any of its Subsidiaries. Any real property and facilities held under
lease by the Company or any of its Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions
as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company
and its Subsidiaries.

 

4.15     INSURANCE.
Each of the Company’s Subsidiaries are insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as management of the Company reasonably believes to be prudent and customary in the businesses in which
the Company and its Subsidiaries are engaged.

 

4.16     REGULATORY
PERMITS. The Company and its Subsidiaries have in full force and effect all certificates, approvals, authorizations and permits
from the appropriate federal, state, local or foreign regulatory authorities and comparable foreign regulatory agencies, necessary
to own, lease or operate their respective properties and assets and conduct their respective businesses in the manner currently
being conducted, and neither the Company nor any such Subsidiary has received any notice of proceedings relating to the revocation
or modification of any such certificate, approval, authorization or permit, except for such certificates, approvals, authorizations
or permits which if not obtained, or such revocations or modifications which, would not have a Material Adverse Effect.

 

4.17     INTERNAL
ACCOUNTING CONTROLS. As of the date of this Agreement, the Investor acknowledges having had the opportunity to conduct its
own due diligence into the Company’s internal controls over financial reporting, and is satisfied that for the purposes
of this Agreement and the Registration Rights Agreement, the Company has acceptable reasonable and appropriate financial and reporting
protocols in effect.

 

    	 	- 12 -	 

     

    

 

4.18     NO
MATERIALLY ADVERSE CONTRACTS, ETC. Neither the Company nor any of its Subsidiaries is subject to any charter, corporate or
other legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers
has or is expected in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party
to any contract or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse
Effect.

 

4.19     TAX
STATUS. The Company and each of its Subsidiaries has made or filed all United States federal and state income and all other
tax returns, reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that
the Company and each of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid
and unreported taxes) and has paid all taxes and other governmental assessments and charges that are material in amount, shown
or determined to be due on such returns, reports and declarations, except those being contested in good faith and has set aside
on its books provision reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns,
reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for any such claim.

 

4.20     CERTAIN
TRANSACTIONS. Except as set forth in Schedule 4.20 and except for transactions pursuant to which the Company makes payments
in the ordinary course of business upon terms no less favorable than the Company could obtain from disinterested third parties
and other than the grant of stock options disclosed in Schedule 4.20, none of the officers, directors, or employees of the Company
is presently a party to any transaction with the Company or any of its Subsidiaries (other than for services as employees, consultants,
officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or
by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any corporation, partnership, trust or other entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

 

4.21     DILUTIVE
EFFECT. The Company understands and acknowledges that the number of shares of Common Stock issuable upon purchases pursuant
to this Agreement will increase in certain circumstances including, but not necessarily limited to, the circumstance wherein the
trading price of the Common Stock declines during the period between the Effective Date and the end of the Open Period. The Company’s
executive officers and directors have studied and fully understand the nature of the transactions contemplated by this Agreement
and recognize that they have a potential dilutive effect on the shareholders of the Company. The board of directors of the Company
has concluded, in its good faith business judgment, and with full understanding of the implications, that such issuance is in
the best interests of the Company. The Company specifically acknowledges that, subject to such limitations as are expressly set
forth in the Registered Offering Transaction Documents, its obligation to issue shares of Common Stock upon purchases pursuant
to this Agreement is absolute and unconditional regardless of the dilutive effect that such issuance may have on the ownership
interests of other shareholders of the Company.

 

4.22     LOCK-UP.
The Company shall cause its officers, insiders, directors, and affiliates or other related parties under control of the Company,
to refrain from selling Common Stock during each Pricing Period.

 

    	 	- 13 -	 

     

    

 

4.23     NO
GENERAL SOLICITATION. Neither the Company, nor any of its affiliates, nor any person acting on its behalf, has engaged in
any form of general solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale
of the Common Stock to be offered as set forth in this Agreement.

 

4.24     NO
BROKERS, FINDERS OR FINANCIAL ADVISORY FEES OR COMMISSIONS. No brokers, finders or financial advisory fees or commissions
will be payable by the Company, its agents or Subsidiaries, with respect to the transactions contemplated by this Agreement.

 

SECTION
V

COVENANTS
OF THE COMPANY

 

5.1       BEST
EFFORTS. The Company shall use all commercially reasonable efforts to timely satisfy each of the conditions set forth in Section
7 of this Agreement.

 

5.2       REPORTING
STATUS. During the Open Period and until one of the following occurs, the Company shall file all reports required to be filed
with the SEC pursuant to the 1934 Act, and the Company shall not terminate its status, or take an action or fail to take any action,
which would terminate its status as a reporting company under the 1934 Act: (i) this Agreement terminates pursuant to Section
8 and the Investor has the right to sell all of the Securities without volume restrictions pursuant to Rule 144 promulgated
under the 1933 Act, or such other exemption, or (ii) the date on which the Investor has sold all the Securities and this Agreement
has been terminated pursuant to Section 8.

 

5.3       USE
OF PROCEEDS. The Company will use the proceeds from the sale of the Securities (excluding amounts paid or to be paid by the
Company for fees as set forth in the Registered Offering Transaction Documents, if any) for general corporate and working capital
purposes and acquisitions or assets, businesses or operations or for other purposes that the board of directors of the Company,
in its good faith deem to be in the best interest of the Company.

 

5.4       FINANCIAL
INFORMATION. During the Open Period, the Company agrees to make available to the Investor via EDGAR or other electronic means
the following documents and information on the forms set forth: (i) within five (5) Trading Days after the filing thereof with
the SEC, a copy of its Annual Reports on Form 10-K, its Quarterly Reports on Form 10-Q, any Current Reports on Form 8-K and any
Registration Statements or amendments filed pursuant to the 1933 Act; (ii) copies of any notices and other information made available
or given to the shareholders of the Company generally, contemporaneously with the making available or giving thereof to the shareholders;
and (iii) within two (2) calendar days of filing or delivery thereof, copies of all documents filed with, and all correspondence
sent to, the Principal Market, any securities exchange or market, or the Financial Industry Regulatory Association, unless such
information is material nonpublic information.

 

5.5       RESERVATION
OF SHARES. The Company shall take all action necessary to at all times have authorized, and reserved the amount of Shares
included in the Registration Statement for issuance pursuant to the Registered Offering Transaction Documents. In the event that
the Company determines that it does not have a sufficient number of authorized shares of Common Stock to reserve and keep available
for issuance as described in this Section 5.5, the Company shall use all commercially reasonable efforts to increase the
number of authorized shares of Common Stock by seeking shareholder approval for the authorization of such additional shares.

 

    	 	- 14 -	 

     

    

 

5.6       LISTING.
The Company shall use all commercially reasonable efforts to promptly secure and maintain the listing of all of the Registrable
Securities (as defined in the Registration Rights Agreement) on the Principal Market and each other national securities exchange
and automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance)
and shall maintain, such listing of all Registrable Securities from time to time issuable under the terms of the Registered Offering
Transaction Documents. Neither the Company nor any of its Subsidiaries shall take any action which would be reasonably expected
to result in the delisting or suspension of the Common Stock on the Principal Market (excluding suspensions of not more than one
(1) Trading Day resulting from business announcements by the Company). The Company shall promptly provide to the Investor copies
of any notices it receives from the Principal Market regarding the continued eligibility of the Common Stock for listing on such
automated quotation system or securities exchange. The Company shall pay all fees and expenses in connection with satisfying its
obligations under this Section 5.6.

 

5.7       FILING
OF FORM 8-K. On or before the date which is four (4) Trading Days after the Execution Date, the Company shall file a Current
Report on Form 8-K with the SEC describing the terms of the transaction contemplated by the Registered Offering Transaction Documents
in the form required by the 1934 Act, if such filing is required.

 

5.8       CORPORATE
EXISTENCE. The Company shall use all commercially reasonable efforts to preserve and continue the corporate existence of the
Company.

 

5.9       NOTICE
OF CERTAIN EVENTS AFFECTING REGISTRATION; SUSPENSION OF RIGHT TO MAKE A PUT. The Company shall promptly notify the Investor
upon the occurrence of any of the following events in respect of a Registration Statement or related prospectus in respect of
an offering of the Securities: (i) receipt of any request for additional information by the SEC or any other federal or state
governmental authority during the period of effectiveness of the Registration Statement for amendments or supplements to the Registration
Statement or related prospectus; (ii) the issuance by the SEC or any other federal or state governmental authority of any stop
order suspending the effectiveness of any Registration Statement or the initiation of any proceedings for that purpose; (iii)
receipt of any notification with respect to the suspension of the qualification or exemption from qualification of any of the
Securities for sale in any jurisdiction or the initiation or notice of any proceeding for such purpose; (iv) the happening of
any event that makes any statement made in such Registration Statement or related prospectus or any document incorporated or deemed
to be incorporated therein by reference untrue in any material respect or that requires the making of any changes in the Registration
Statement, related prospectus or documents so that, in the case of a Registration Statement, it will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading, and that in the case of the related prospectus, it will not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; and (v) the Company’s reasonable determination that a post-effective
amendment or supplement to the Registration Statement would be appropriate, and the Company shall promptly make available to Investor
any such supplement or amendment to the related prospectus. The Company shall not deliver to Investor any Put Notice during the
continuation of any of the foregoing events in this Section 5.9.

 

5.10     TRANSFER
AGENT. Upon effectiveness of the Registration Statement, and for so long as the Registration Statement is effective, following
delivery of a Put Notice, the Company shall deliver instructions to its transfer agent to issue Shares to the Investor that are
covered for resale by the Registration Statement free of restrictive legends.

 

5.11     ACKNOWLEDGEMENT
OF TERMS. The Company hereby represents and warrants to the Investor that: (i) it is voluntarily entering into this Agreement
of its own freewill, (ii) it is not entering this Agreement under economic duress, (iii) the terms of this Agreement are reasonable
and fair to the Company, and (iv) the Company has had independent legal counsel of its own choosing review this Agreement, advise
the Company with respect to this Agreement, and represent the Company in connection with this Agreement.

 

    	 	- 15 -	 

     

    

 

SECTION
VI

CONDITIONS
OF THE COMPANY’S ELECTION TO SELL

 

There
is no obligation hereunder of the Company to issue and sell the Securities to the Investor. However, an election by the Company
to issue and sell the Securities hereunder, from time to time as permitted hereunder, is further subject to the satisfaction,
at or before each Closing Date, of each of the following conditions set forth below. These conditions are for the Company’s
sole benefit and may be waived by the Company at any time in its sole discretion.

 

6.1       The
Investor shall have executed this Agreement and the Registration Rights Agreement and delivered the same to the Company.

 

6.2       The
Investor shall have delivered to the Company a Put Settlement Sheet in the form attached here to as Exhibit C on the Put
Notice Date.

 

6.3       No
statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated
by this Agreement.

 

SECTION
VII

FURTHER
CONDITIONS OF THE INVESTOR’S OBLIGATION TO PURCHASE

 

The
obligation of the Investor hereunder to purchase Securities is subject to the satisfaction, on or before each Closing Date, of
each of the following conditions set forth below.

 

7.1  
     The Company shall have executed the Registered Offering Transaction Documents and delivered the
same to the Investor.

 

7.2   
    The Common Stock shall be authorized for quotation on the Principal Market and trading in the Common
Stock shall not have been suspended by the Principal Market or the SEC, at any time beginning on the date hereof and through
and including the respective Closing Date (excluding suspensions of not more than one (1) Trading Day resulting from business
announcements by the Company, provided that such suspensions occur prior to the Company’s delivery of the Put Notice
related to such Closing).

 

7.3   
    The representations and warranties of the Company shall be true and correct in all material respects
as of the date when made and as of the applicable Closing Date as though made at that time and the Company shall have
materially performed, satisfied and complied with the covenants, agreements and conditions required by the Registered
Offering Transaction Documents to be performed, satisfied or complied with by the Company on or before such Closing Date. The
Investor may request an update as of such Closing Date regarding the representation contained in Section
4.3.

 

    	 	- 16 -	 

     

    

 

7.4   
    The Company shall have executed and delivered to the Investor the certificates representing, or have
executed electronic book-entry transfer of, the Securities (in such denominations as the Investor shall request) being
purchased by the Investor at such Closing.

 

7.5   
    The board of directors of the Company shall have adopted resolutions consistent with Section
4.2(ii) (the “Resolutions”) and such Resolutions shall not have been materially amended or rescinded
prior to such Closing Date.

 

7.6   
    No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted,
entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the
consummation of any of the transactions contemplated by this Agreement.

 

7.7   
    The Registration Statement shall be effective on each Closing Date and no stop order suspending the
effectiveness of the Registration statement shall be in effect or to the Company’s knowledge shall be pending or
threatened. Furthermore, on each Closing Date (i) neither the Company nor the Investor shall have received notice that the
SEC has issued or intends to issue a stop order with respect to such Registration Statement or that the SEC otherwise has
suspended or withdrawn the effectiveness of such Registration Statement, either temporarily or permanently, or intends or has
threatened to do so (unless the SEC’s concerns have been addressed), and (ii) no other suspension of the use or
withdrawal of the effectiveness of such Registration Statement or related prospectus shall exist.

 

7.8   
    At the time of each Closing, the Registration Statement (including information or documents
incorporated by reference therein) and any amendments or supplements thereto shall not contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading or which would require public disclosure or an update supplement to the prospectus.

 

7.9   
    If applicable, the shareholders of the Company shall have approved the issuance of any Shares in
excess of the Maximum Common Stock Issuance in accordance with Section 2.6 or the Company shall have obtained
appropriate approval pursuant to the requirements of Delaware law and the Company’s Articles of Incorporation and
By-laws.

 

7.10       The
conditions to such Closing set forth in Section 2.4 shall have been satisfied on or before such Closing Date.

 

7.11       The
Company shall have certified to the Investor the number of Shares of Common Stock outstanding when a Put Notice is given to the
Investor. The Company’s delivery of a Put Notice to the Investor constitutes the Company’s certification of the existence
of the necessary number of shares of Common Stock reserved for issuance.

 

SECTION
VIII

TERMINATION

 

This
Agreement shall terminate upon any of the following events:

 

		i.	when
                                         the Investor has purchased an aggregate of Three Million Dollars ($3,000,000) in the
                                         Common Stock of the Company pursuant to this Agreement;

 

		ii.	on
                                         the date which is thirty-six (36) months after the Effective Date; or

 

    	 	- 17 -	 

     

    

 

		iii.	at
                                         such time that the Registration Statement is no longer in effect; or

 

		iv.	at
                                         any time at the election of the Company upon 15 days written notice.

 

Any
and all shares, or penalties, if any, due under this Agreement shall be immediately payable and due upon termination of this Agreement.

 

SECTION
IX

SUSPENSION

 

This
Agreement shall be suspended upon any of the following events, and shall remain suspended until such event is rectified:

 

		i.	The
                                         trading of the Common Stock is suspended by the SEC, the Principal Market or FINRA for
                                         a period of two (2) consecutive Trading Days during the Open Period; or,

 

		ii.	During
                                         the Open Period, the Common Stock ceases to be registered under the 1934 Act or listed
                                         or traded on the Principal Market or the Registration Statement is no longer effective
                                         (except as permitted hereunder).

 

Immediately
upon the occurrence of one of the above-described events, the Company shall send written notice of such event to the Investor.

SECTION
X

MISCELLANEOUS

 

10.1    Law
Governing this Agreement. This Agreement shall be governed by,
and construed and interpreted in accordance with, the substantive laws of the State of California without giving effect to any
conflict of laws rule or principle that might require the application of the laws of another jurisdiction. Any dispute, claim,
suit, action or other legal proceeding arising out of the transactions contemplated by this Agreement or the rights and obligations
of each of the parties shall be brought only in a competent court in San Diego, California or in the federal courts of the United
States of America located in San Diego, California. The parties to this Agreement hereby irrevocably waive any objection to jurisdiction
and venue of any action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based
upon forum non conveniens. The parties executing this Agreement and other agreements referred to herein or delivered
in connection herewith agree to submit to the in personam jurisdiction of such courts. The prevailing party shall be entitled
to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Agreement
or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law,
then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the
validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process
and consents to process being served in any suit, action or proceeding in connection with this Agreement or any other Transaction
Documents by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.

 

    	 	- 18 -	 

     

    

 

10.2     LEGAL
FEES; AND MISCELLANEOUS FEES. Except as otherwise set forth in the Registered Offering Transaction Documents (including but
not limited to Section 5 of the Registration Rights Agreement), each party shall pay the fees and expenses of its advisers, counsel,
accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. Any attorneys’ fees and expenses incurred by either the Company or
the Investor in connection with the preparation, negotiation, execution and delivery of any amendments to this Agreement or relating
to the enforcement of the rights of any party, after the occurrence of any breach of the terms of this Agreement by another party
or any default by another party in respect of the transactions contemplated hereunder, shall be paid on demand by the party which
breached the Agreement and/or defaulted, as the case may be. The Company shall pay all stamp and other taxes and duties levied
in connection with the issuance of any Securities.

 

10.3     COUNTERPARTS.
This Agreement may be executed in any number of counterparts and by the different signatories hereto on separate counterparts,
each of which, when so executed, shall be deemed an original, but all such counterparts shall constitute but one and the same
instrument. This Agreement may be executed by facsimile transmission, PDF, electronic signature or other similar electronic means
with the same force and effect as if such signature page were an original thereof.

 

10.4     HEADINGS;
SINGULAR/PLURAL. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the
interpretation of, this Agreement. Whenever required by the context of this Agreement, the singular shall include the plural and
masculine shall include the feminine.

 

10.5     SEVERABILITY.
If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability
shall not affect the validity or enforceability of the remainder of this Agreement in that jurisdiction or the validity or enforceability
of any provision of this Agreement in any other jurisdiction.

 

10.6     ENTIRE
AGREEMENT; AMENDMENTS. This Agreement is the FINAL AGREEMENT between the Company and the Investor with respect to the terms
and conditions set forth herein, and, the terms of this Agreement may not be contradicted by evidence of prior, contemporaneous,
or subsequent oral agreements of the Parties.

 

10.7     NOTICES.
Any notices or other communications required or permitted to be given under the terms of this Agreement must be in writing and
will be deemed to have been delivered (i) upon receipt, when delivered personally; (ii) upon receipt, when sent by electronic
mail (provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party);
or (iii) one (1) day after deposit with a nationally recognized overnight delivery service, in each case properly addressed to
the party to receive the same. The addresses and email addresses for such communications shall be:

 

	 	If
        to the Company:

         
	 	HealthLynked
        Corp.

        1726
        Medical Blvd Suite 101

        Naples,
        FL 34110

        Attn:
        George O’Leary

        Email:
        goleary@sksconsulting.us

	 	 	 	 
	 	If
    to the Investor:	 	Iconic
        Holdings, LLC

        2251
        San Diego Ave. #B150

        San
        Diego, CA 92110

        Attn:
        Michael Sobeck

        Email:
        admin@tangierscapital.com

 

Each
party shall provide five (5) business days prior written notice to the other party of any change in address or email address.

 

    	 	- 19 -	 

     

    

 

10.8     NO
ASSIGNMENT. This Agreement may not be assigned.

 

10.9     NO
THIRD PARTY BENEFICIARIES. This Agreement is intended for the benefit of the parties hereto and is not for the benefit of,
nor may any provision hereof be enforced by, any other person.

 

10.10   SURVIVAL.
The representations and warranties of the Company and the Investor contained in Sections 3 and 4, the agreements and covenants
set forth in Section 5 and this Section 11 shall survive each of the Closings and the termination of this Agreement.

 

10.11  PUBLICITY.
The Company and the Investor shall consult with each other in issuing any press releases or otherwise making public
statements with respect to the transactions contemplated hereby and no party shall issue any such press release or otherwise
make any such public statement without the prior consent of the other party, which consent shall not be unreasonably withheld
or delayed, except that no prior consent shall be required if such disclosure is required by law, as determined solely by the
Company in consultation with its counsel. The Investor acknowledges that this Agreement and all or part of the Registered
Offering Transaction Documents may be deemed to be “material contracts” as that term is defined by Item
601(b)(10) of Regulation S-K, and that the Company may therefore be required to file such documents as exhibits to reports or
registration statements filed under the 1933 Act or the 1934 Act. The Investor further agrees that the status of such
documents and materials as material contracts shall be determined solely by the Company, in consultation with its
counsel.

 

10.12   EXCLUSIVITY.
The Company shall not pursue an equity line transaction similar to the transactions contemplated in this Agreement with any other
person or entity until the earlier of (i) the Effective Date and (ii) termination of this Agreement in accordance with Section
8.

 

10.13   FURTHER
ASSURANCES. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall
execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request
in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated
hereby.

 

10.14   NO
STRICT CONSTRUCTION. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party, as the parties mutually agree that
each has had a full and fair opportunity to review this Agreement and seek the advice of counsel on it.

 

10.15   REMEDIES.
The Investor shall have all rights and remedies set forth in this Agreement and the Registration Rights Agreement and all rights
and remedies which such holders have been granted at any time under any other agreement or contract and all of the rights which
the Investor has by law. Any person having any rights under any provision of this Agreement shall be entitled to enforce such
rights specifically (without posting a bond or other security), to recover damages by reason of any default or breach of any provision
of this Agreement, including the recovery of reasonable attorney’s fees and costs, and to exercise all other rights granted
by law.

 

    	 	- 20 -	 

     

    

 

10.16   PAYMENT
SET ASIDE. To the extent that the Company makes a payment or payments to the Investor hereunder or under the Registration
Rights Agreement or the Investor enforces or exercises its rights hereunder or thereunder, and such payment or payments or the
proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential,
set aside, recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee,
receiver or any other person under any law (including, without limitation, any bankruptcy law, state or federal law, common law
or equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to
be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such enforcement
or setoff had not occurred.

 

10.17   COMMITMENT
FEE. Upon the date of execution of this Agreement, the Company shall be required to issue to the Purchaser a 10% $50,000 promissory
note as a commitment fee (the “Commitment Fee Note”). In the event that the S-1 is declared effective within
120 days following document execution, $20,000 will be automatically deducted from the balance of the Commitment Fee Note. In
the event that the S-1 is declared effective within 135 days (but more than 120 days) following document execution, $12,500 will
be automatically deducted from the balance of the Commitment Fee Note. The Company agrees that the issuance of the Commitment
Fee Note is a material obligation and that the note is considered fully earned as of the date of execution of this Agreement,
regardless of whether or not the Company files the S-1 or is successful in having it deemed effective by the SEC.

 

10.18   WARRANTS.
For each fifty thousand dollars ($50,000) that the Purchaser tenders to the Company for the purchase of shares of Common Stock
hereunder, the Company shall grant Warrants to the Investor for the purchase of an equivalent number of shares of Common Stock.
The form of the Warrant is attached hereto as Exhibit D. The Warrants shall expire five (5) years from their respective grant
date. The exercise price of the Warrants shall be equal to 130% of the weighted average purchase price for the respective “$50,000
increment.” The Warrants shall have a “cashless” or “net exercise” provision.

 

SECTION
XI

NON-DISCLOSURE
OF NON-PUBLIC INFORMATION

 

The
Company shall not disclose non-public information to the Investor, its advisors, or its representatives.

 

Nothing
in the Registered Offering Transaction Documents shall require or be deemed to require the Company to disclose non-public information
to the Investor or its advisors or representatives, and the Company represents that it does not disseminate non-public information
to any investors who purchase stock in the Company in a public offering, to money Managing Members or to securities analysts,
provided, however, that notwithstanding anything herein to the contrary, the Company will, as hereinabove provided, immediately
notify the advisors and representatives of the Investor and, if any, underwriters, of any event or the existence of any circumstance
(without any obligation to disclose the specific event or circumstance) of which it becomes aware, constituting non-public information
(whether or not requested of the Company specifically or generally during the course of due diligence by such persons or entities),
which, if not disclosed in the prospectus included in the Registration Statement would cause such prospectus to include a material
misstatement or to omit a material fact required to be stated therein in order to make the statements, therein, in light of the
circumstances in which they were made, not misleading. Nothing contained in this Section 12 shall be construed to mean
that such persons or entities other than the Investor (without the written consent of the Investor prior to disclosure of such
information) may not obtain non-public information in the course of conducting due diligence in accordance with the terms of this
Agreement and nothing herein shall prevent any such persons or entities from notifying the Company of their opinion that based
on such due diligence by such persons or entities, that the Registration Statement contains an untrue statement of material fact
or omits a material fact required to be stated in the Registration Statement or necessary to make the statements contained therein,
in light of the circumstances in which they were made, not misleading.

    	 	- 21 -	 

     

    

 

SECTION
XII

ACKNOWLEDGEMENTS
OF THE PARTIES

 

Notwithstanding
anything in this Agreement to the contrary, the parties hereto hereby acknowledge and agree to the following: (i) the Investor
makes no representations or covenants that it will not engage in trading in the securities of the Company, other than the Investor
will not short or pre-sell, either directly or indirectly through its affiliates, principals or advisors, the Common Stock of
the Company at any time; (ii) the Company shall comply with its obligations under Section 5.8 in a timely manner; (iii) the Company
has not and shall not provide material non-public information to the Investor unless prior thereto the Investor shall have executed
a written agreement regarding the confidentiality and use of such information; and (iv) the Company understands and confirms that
the Investor will be relying on the acknowledgements set forth in clauses (i) through (iii) above if the Investor effects any
transactions in the securities of the Company.

 

[Signature
Page to Follow.]

 

    	 	- 22 -	 

     

    

 

Your
signature on this Signature Page evidences your agreement to be bound by the terms and conditions of the Investment Agreement
as of the date first written above. The undersigned signatory hereby certifies that he has read and understands the Investment
Agreement, and the representations made by the undersigned in this Investment Agreement are true and accurate, and agrees to be
bound by its terms.

 

	 	ICONIC
    HOLDINGS, LLC
	 	 	 
	 	By:	         
	 	Name:	 
	 	Title:
     	Manager
	 	 	 
	 	HEALTHYLYNKED
    CORP.
	 	 	 
	 	By:	 
	 	Name:	George
    G. O’Leary
	 	Title:	Chief Financial
    Officer

  

[SIGNATURE
PAGE OF INVESTMENT AGREEMENT]

 

    	 	- 23 -	 

     

    

 

LIST
OF EXHIBITS

 

	EXHIBIT
    A	Registration
    Rights Agreement
	 	 
	EXHIBIT
    B	Put Notice
	 	 
	EXHIBIT
    C	Put Settlement
    Sheet
	 	 
	EXHIBIT
    D	Form of
    Warrant

 

    

     

    

 

EXHIBIT
A

 

REGISTRATION
RIGHTS AGREEMENT

 

See
attached.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

     

    

 

EXHIBIT
B

 

FORM
OF PUT NOTICE

 

Date:

 

RE:
Put Notice Number __

 

Dear
Mr.__________,

 

This
is to inform you that as of today, HealthLynked Corp., a Nevada corporation (the “Company”), hereby elects to exercise
its right pursuant to the Investment Agreement to require Iconic Holdings, LLC to purchase shares of its common stock. The Company
hereby certifies that:

 

Put
Amount in Shares__________.

 

The
Pricing Period runs from _______________ until _______________.

 

The
current number of shares of common stock issued and outstanding is: _________________.

 

The
number of shares currently available for resale on the S-1 is: ________________________.

 

Regards,

 

	HealthLynked
    Corp.	 
	 	 	 
	By:	       	 
	Name:	George
    G. O’Leary	 
	Title:	Chief Financial
    Officer	 

 

    

     

    

 

EXHIBIT
C

 

PUT
SETTLEMENT SHEET

 

Date:
________________

 

Dear
________,

 

Pursuant
to the Put given by HealthLynked Corp. to Iconic Holdings, LLC. (“IH”) on _________________ 201_, we are now submitting
the purchase price for the shares of common stock.

 

Purchase
Price per Share _________________.

 

Shares
Being Purchased___________________.

 

Total
Purchase Price _____________________.

 

Please
have a certificate bearing no restrictive legend issued to TG immediately and sent via DWAC to the following account:

 

[INSERT]

 

If
not DWAC eligible, please send FedEx Priority Overnight to:

 

[INSERT
ADDRESS]

 

Once
these shares are received by us, we will have the funds wired to the Company.

 

Regards,

 

	ICONIC
    HOLDINGS, LLC	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title:	Manager	 

 

    

     

    

 

EXHIBIT
D

 

FORM
OF WARRANT

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

     

    

 

SCHEDULE
4.3

 

4.3(ii)

 

$440,299
outstanding notes issued to Dr. Michael Dent, CEO and director, as of May 31, 2016 that are subordinate to the secured note of
Investor.

 

4.3(iii)

 

Warrants
issued to Delaney Equity Group of 5% warrant coverage, warrants issued to Urania Holdings LLC at $0.10 per warrant share tied
to a $100,000 investment in HealthLynked Corporation at $0.08 per share, and stock options issued to Dr. Michael T. Dent and George
G O’Leary as set forth in their respective employment agreements

 

4.3(
iv)

 

Company
agreed to register common stock issued to certain prior investors, including employees of the Company and “friends and family”

 

4.7

 

The
Company is moving from solely providing specialized health services to providing both specialized health services as well as healthcare
information services, as discussed with the Investor.

 

4.14

 

Lien
held by Florida Community Bank to be removed in connection with a secured note financing with Investor.

 

4.20

 

$440,299
outstanding notes issued to Dr. Michael Dent, CEO and director, that are subordinate to the secured note of Investor.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00266-of-00352.parquet"}]]